Labopharm's Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria



    - Product Now Being Sold in 14 Countries Worldwide -

    LAVAL, QC, July 31 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ:   DDSS) today
announced that its once-daily formulation of tramadol has been launched in the
following countries:

    South Korea - Labopharm's marketing partner for South Korea, WhanIn
Pharmaceutical Co. Ltd., launched the product in July under the brand name
TramaConti CR(R).

    Australia - Labopharm's marketing partner for Australia, iNova
Pharmaceuticals (Australia) Pty Limited launched the product in July under the
brand name Durotram XR(R).

    Romania - Labopharm's marketing partner for Romania, CSC Pharmaceuticals,
launched the product in July under the brand name Noax(R) Uno.

    Austria - Labopharm's marketing partner for Austria, CSC Pharmaceuticals,
launched the product in June under the brand name Noax(R) Uno.

    "With these launches, our once-daily tramadol product is now being sold
in 14 countries that, combined, account for almost 55% of the world's market
for tramadol products," said James R. Howard-Tripp, President and Chief
Executive Officer, Labopharm Inc. "South Korea and Australia, in particular,
represent significant opportunities as the 6th and 12th largest markets for
tramadol products in the world, respectively. We look forward to leveraging
the experience we have gained through our previous European and Canadian
launches and working with our marketing partners to maximize our product's
potential in these markets."
    Labopharm's product is available in 100mg, 200mg and 300mg dosage
strengths in Australia, Austria and Romania and in 100mg and 200mg dosage
strengths in South Korea. The 300 mg dosage strength is approved for sale in
South Korea and may be marketed at a later date.

    About Labopharm's Once-Daily Tramadol Product

    Labopharm's once-daily tramadol product is based on the Company's
proprietary Contramid(R) technology, which provides a dual matrix delivery
system allowing both rapid and sustained drug release that maintains blood
levels within the therapeutic range providing a full 24 hours of pain relief.
The Company believes that maintaining drug concentrations within the
therapeutic range has the advantage of fewer and less severe side effects
while maintaining efficacy. Under its global commercialization program,
Labopharm's once-daily tramadol product has been launched in 14 countries,
including the five largest markets in Europe and Canada and is approved in
16 other countries. Including those countries in which its product has been
launched, Labopharm has licensing and distribution agreements in place for
more than 50 markets globally.

    About Labopharm Inc.

    Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company also has a
robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become an integrated, international,
specialty pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
www.labopharm.com.

    This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.





For further information:

For further information: At Labopharm, Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group, Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
jhogan@equicomgroup.com; French: Joe Racanelli, Tel: (514) 844-7997,
jracanelli@equicomgroup.com

Organization Profile

LABOPHARM INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890